Wave life sciences reports third quarter 2022 financial results and provides business update

Announced positive update in third quarter from select-hd trial in hd; single doses of wve-003 appeared generally safe and well-tolerated and suggested allele-selective reduction of mhtt protein in csf
WVE Ratings Summary
WVE Quant Ranking